McKenna Mark C. — SEC insider filings

SEC reporting owner CIK 1749623. 25 insider filings on record with FilingPulse; latest filed 2026-10-20.

Transaction summary — filings shown

Covers all 25 filings on record, filed 2021-11-16 to 2026-10-20. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Prometheus Biosciences, Inc. (RXDX)Chairman, President and CEO, Director10—7 legs · 125,000 sh · $14,988,43133
Apogee Therapeutics, Inc. (APGE)Director62 legs · 20,000 sh · $990,775—10
NewAmsterdam Pharma Co N.V. (NAMS)Director3——5
Spyre Therapeutics, Inc. (SYRE)Director3——3
BridgeBio Oncology Therapeutics, Inc. (BBOT)—1——2
Freenome, Inc. (FRNM)—1——2
TCGX Acquisition Corp. II (TCXB)Director1———

Insider filings — McKenna Mark C.

FiledFormIssuerReported transactionsSource
2026-10-203TCGX Acquisition Corp. II (TCXB)Holdings only — no transactions reportedEDGAR
2026-09-034Apogee Therapeutics, Inc. (APGE)Disposition to issuer (D): 20,000 · Disposition to issuer (D): 150,000 (derivative) · Disposition to issuer (D): 10,370 (derivative) · Disposition to issuer (D): 14,461 (derivative) · Disposition to issuer (D): 7,657 (derivative)EDGAR
2026-07-224Freenome, Inc. (FRNM)Conversion (C): 30,000 · Conversion (C): 30,000 (derivative)EDGAR
2026-06-114Apogee Therapeutics, Inc. (APGE)Grant/award (A): 7,657 (derivative) @ $0EDGAR
2026-05-294Spyre Therapeutics, Inc. (SYRE)Grant/award (A): 8,026 (derivative) @ $0EDGAR
2026-01-094NewAmsterdam Pharma Co N.V. (NAMS)Grant/award (A): 3,400 · Grant/award (A): 15,300 (derivative) @ $0EDGAR
2025-08-114BridgeBio Oncology Therapeutics, Inc. (BBOT)Option exercise (M): 30,000 · Option exercise (M): 30,000 (derivative) @ $0EDGAR
2025-06-204Apogee Therapeutics, Inc. (APGE)Grant/award (A): 14,461 (derivative) @ $0EDGAR
2025-06-024Spyre Therapeutics, Inc. (SYRE)Grant/award (A): 25,000 (derivative) @ $0EDGAR
2025-01-084NewAmsterdam Pharma Co N.V. (NAMS)Grant/award (A): 6,960 · Grant/award (A): 32,500 (derivative) @ $0EDGAR
2024-12-164Apogee Therapeutics, Inc. (APGE)Purchase (P): 7,500 @ $49.02 · Purchase (P): 12,500 @ $49.85EDGAR
2024-07-194NewAmsterdam Pharma Co N.V. (NAMS)Grant/award (A): 72,500 (derivative) @ $0EDGAR
2024-06-074Apogee Therapeutics, Inc. (APGE)Grant/award (A): 10,370 (derivative) @ $0EDGAR
2024-02-054Spyre Therapeutics, Inc. (SYRE)Grant/award (A): 40,000 (derivative) @ $0EDGAR
2023-08-214Apogee Therapeutics, Inc. (APGE)Grant/award (A): 50,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0EDGAR
2023-06-164Prometheus Biosciences, Inc. (RXDX)Disposition to issuer (D): 178,098 · Disposition to issuer (D): 161,105 (derivative) · Disposition to issuer (D): 132,741 (derivative) · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 481,725 (derivative) · Disposition to issuer (D): 566,307 (derivative) · +3 moreEDGAR
2023-06-024Prometheus Biosciences, Inc. (RXDX)Option exercise (M): 122,528 @ $2.90 · Option exercise (M): 3 @ $1.70 · Option exercise (M): 122,528 (derivative) @ $0 · Option exercise (M): 3 (derivative) @ $0EDGAR
2023-03-174Prometheus Biosciences, Inc. (RXDX)Option exercise (M): 25,000 @ $2.90 · Sale (S): 25,000 @ $116.14 · Option exercise (M): 25,000 (derivative) @ $0EDGAR
2023-03-034Prometheus Biosciences, Inc. (RXDX)Option exercise (M): 700 @ $3.70 · Sale (S): 700 @ $125.26 · Option exercise (M): 10,620 @ $3.70 · Sale (S): 10,620 @ $125.13 · Option exercise (M): 700 (derivative) @ $0 · Option exercise (M): 10,620 (derivative) @ $0EDGAR
2023-02-174Prometheus Biosciences, Inc. (RXDX)Option exercise (M): 25,000 @ $2.90 · Sale (S): 25,000 @ $119.42 · Option exercise (M): 25,000 @ $3.70 · Sale (S): 25,000 @ $119.87 · Option exercise (M): 13,680 @ $3.70 · Sale (S): 13,680 @ $125.10 · +3 moreEDGAR
2023-01-194Prometheus Biosciences, Inc. (RXDX)Option exercise (M): 25,000 @ $2.90 · Sale (S): 25,000 @ $118.99 · Option exercise (M): 25,000 (derivative) @ $0EDGAR
2022-12-134Prometheus Biosciences, Inc. (RXDX)Grant/award (A): 37,113 @ $0 · Grant/award (A): 128,930 (derivative) @ $0EDGAR
2022-05-204Prometheus Biosciences, Inc. (RXDX)Grant/award (A): 246,639 (derivative) @ $0EDGAR
2021-12-034Prometheus Biosciences, Inc. (RXDX)Option exercise (M): 15,400 @ $2.90 · Option exercise (M): 15,400 (derivative) @ $0EDGAR
2021-11-164Prometheus Biosciences, Inc. (RXDX)Grant/award (A): 290,000 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2021-11-16 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1749623 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs